Skip to main content
. 2014 May 27;66(6):1492–1503. doi: 10.1002/art.38392

Figure 1.

Figure 1

ES‐62 differentially targets interleukin‐17 (IL‐17)– and IL‐22–producing draining lymph node (DLN) cells in mice with collagen‐induced arthritis (CIA). A, Percent CIA incidence, mean ± SEM paw width, and mean ± SEM articular (clinical) score at various time points in a representative experiment (n = 7 phosphate buffered saline [PBS]–treated mice and 7 ES‐62–treated mice) (first through third panels), and mean ± SEM articular score (pooled from 6 independent experiments) at the time of removal from the experiment for all mice (fourth panel; n = 38 PBS‐treated mice and 36 ES‐62–treated mice) and mice that had developed CIA (fifth panel; n = 34 PBS‐treated mice and 24 ES‐62–treated mice). B, Number of DLN cells in naive mice (n = 9), PBS‐treated mice with CIA (n = 32), and ES‐62–treated mice with CIA (n = 25), and representative plots of intracellular IL‐22 and IL‐17 expression from experiments using medium‐treated or phorbol myristate acetate plus ionomycin (PMA/iono)–stimulated DLN cells and CD4+ T cells from PBS‐treated mice with CIA. C and D, Percentages of DLN cells (C) or CD4+ T cells (D) expressing IL‐17 or IL‐22 in PBS‐treated mice with CIA (n = 32) and ES‐62–treated mice with CIA (n = 24). In B (left panel), C, and D, each symbol represents an individual mouse; bars show the mean. ∗ = P < 0.05 (versus ES‐62 on the days indicated, in the second and third panels of A); ∗∗ = P < 0.01; ∗∗∗ = P < 0.001.